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Asymmetric	organocatalytic	synthesis	of	tertiary	azomethyl	
alcohols:	key	intermediates	towards	azoxy	compounds	and	α-
hydroxy-β-amino	esters	
José	A.	Carmona,a	Gonzalo	de	Gonzalo,b	Inmaculada	Serrano,b	Ana	M.	Crespo-Peña,a	Michal	
Šimek,a	David	Monge,*,b	Rosario	Fernández*,b	and	José	M.	Lassaletta*,a	
A	 series	 of	 peracylated	 glycosamine-derived	 thioureas	 has	 been	 synthesized	 and	 its	 behavior	 as	 bifunctional	
organocatalysts	 has	 been	 tested	 in	 the	 enantioselective	 nucleophilic	 addition	 of	 formaldehyde	 tert-butyl	 hydrazone	 to	
aliphatic	α-keto	esters	for	the	synthesis	of	tertiary	azomethyl	alcohols.	Using	the	1,3,4,6-tetra-O-acetyl-2-amino-2-deoxy-
β-D-glucosamine	derived	3,5-bis-(trifluoromethyl)phenyl	thiourea	the	reaction	could	be	accomplished	with	high	yields	(75-
98%)	 and	moderate	 enantioselectivities	 (50-64%	ee).	 Subsequent	 high-yielding	 and	 razemization-free	 tranformations	 of	
both	 aromatic-	 and	 aliphatic-substituted	 diazene	 products	 in	one	 pot	 fashion	 provides	 a	 direct	 entry	 to	 valuable	 azoxy	
compounds	and	α-hydroxy-β-amino	esters.	
	
Introduction	
Chiral	 non-racemic	 tertiary	 alcohols	 and	 derivatives	 bearing	
aryl	 or	 alkyl	 substituents	 at	 the	 stereogenic	 center	 are	
recurrent	scaffolds	 in	many	bioactive	molecules.	The	selected	
examples	 shown	 in	 Figure	 1	 include	 lactones	 Campothecin1	
and	 Tripranavir,2	 β-amino	 alcohol	 derivative	 SSR-241586,3		
Voriconazole,4	 and	 2-substituted	 α-hydroxy-β-amino	 acids	
(isoserines)	 which	 are	 present	 in	 several	 taxoid-based	
anticancer	 agents.5	 The	 increasing	 interest	 in	 known	 or	
predicted	 biological	 properties	 exerted	 by	 2-alkyl	 or	 2-aryl	
substituted	 isoserine	 fragments,	 for	 example	 in	
conformationally	 restricted	 peptidomimetics,6	 contrast,	
however,	with	 the	narrow	palette	of	available	methodologies	
for	 the	 asymmetric	 synthesis	 of	 suitable	 precursors	 for	 such	
molecules.7	 Therefore,	 there	 is	 a	 strong	 interest	 in	 the	
introduction	 of	 molecular	 diversity	 based	 on	 functionalized	
tertiary	 alcohols.	 One	 straightforward	 approach	 relies	 on	 the	
asymmetric	nucleophilic	addition	 to	ketones	and	derivatives.8	
During	years,	we	have	extensively	investigated	the	nucleophilic	
reactivity	 of	 formaldehyde	 N,N-dialkyl	 hydrazones	 for	 the	
stereoselective	introduction	of	single-carbon	functional	groups	
into	several	electrophilic	substrates.9		
More	recently,	we	have	also	exploited	the	superior		
	 	
Figure	1.	Bioactive	tertiary	alcohols	and	derivatives.	
performance	 of	 formaldehyde	 tert-butyl	 hydrazone	 (1)10	 in	
combination	with	organocalytic	 activations.11	 The	asymmetric	
nucleophilic	 addition	 of	 1	 to	 aryl-substituted	 di-carbonyl	
compounds	such	as	α-keto	esters	2	(Scheme	1,	A)10a	isatins,10c	
and	 related	 bidentate	 electrophiles	 such	 as	 α-keto	
phosphonates10d	 using	 BINAM-bis-urea	 as	 the	 organocatalyst	
provides	densely	 functionalized	azomethyl	 carbinols	 (formally	
hetero-carbonyl-ene	products),	which	could	be	further		
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Scheme	1.	Synthesis	of	aryl-	and	alkyl-substituted	azomethyl	tertiary	alcohols	3:	
a	 route	 to	 biologically	 relevant	 azoxy	 compounds	 4	 and	 α-hydroxy-β-amino	
esters	5.	
transformed	 into	 enantioenriched	 tertiary	 α-aryl	 α-hydroxy	
aldehydes	 and	 derivatives	 thereof.	 In	 the	 originally	 proposed	
working	model,	a	bifunctional	behaviour	by	the	organocatalyst	
results	 in	 the	 activation	 of	 both	 the	 hydrazone	 (via	 NH–
O=Chydrogen	 bonds)	 and	 the	 di-oxygenated	 electrophile	
(using	a	second	urea	unit	as	multiple	H-bond	donor),	while	the	
stereochemical	outcome	is	explained	by	the	relative	bulkiness	
of	the	aromatic	group,	oriented	away	from	the	more	crowded	
inner	 region	 of	 this	 ternary	 complex.	 In	 spite	 of	 the	
experimental	 support	 collected	 for	 this	 model	 when	 ethyl	
phenyl	 glyoxylate	 was	 used	 as	 the	 substrate,10a	 preliminary	
experiments	 performed	 with	 aliphatic	 derivatives	 revealed	 a	
poorer	 enantioselectivity,	 suggesting	 a	priori	 that	 any	 kind	of	
π–π	 interactions	 might	 contribute	 to	 the	 stabilization	 of	 the	
transition	state.		
Aiming	 to	 expand	 the	 scope	 and	 applicability	 of	 azomethyl	
tertiary	 alcohols	 3,	 we	 report	 herein	 on	 the	 use	 of	 novel	
saccharide-based	 organocatalysts	 for	 accessing	
enantiomerically	enriched	alkyl-substituted	products	and	their	
subsequent	one	pot	transformations	into	azoxymethyl	alcohols	
4	and	α-hydroxy-β-amino	esters	5	(Scheme	1,	B).	
	
	
	
Results	and	discussion	
Synthesis	of	alkyl-substituted	azomethyl	alcohols	3	
Preliminary	 experiments	 towards	 alkyl-substituted	 adducts	 3	
were	performed	with	commercially	available	ethyl	3-methyl-2-
oxobutanoate	 (2a)	 as	 model	 substrate	 (Table	 1).	 At	 room	
temperature,	the	reaction	of	1	with	2a	afforded	the	azomethyl	
alcohol	3a	 at	 a	 reasonable	 rate	 (85%	 conversion	 after	 2	 h	 in	
toluene	 (entry	 1).	 Cooling	 to	 –15	 °C	 strongly	 decelerated	 the	
uncatalyzed	reaction	(entry	2),	while	a	significant	acceleration	
by	the	Schreiner`s	thiourea	I	(10	mol%)	was	observed	at	this	
Table	1.	Screening	of	organocatalysts	in	the	model	reaction.a	
	
	
Entry	 Cat.	 T	(°C)	 t	(h)	 Conv.	(%)b	 ee	(%)c,d	
1	 none	 rt	 2	 85	 -	
2	 none	 –15	 48	 30	 -	
3	 I	 –15	 48	 >95	 -	
4	 II	 –15	 48	 66	 40	(S)	
5	 III	 –15	 48	 >95	 72	(R)	
6	 IV	 –15	 48	 >95	 10	(R)	
7	 V	 –15	 48	 85	 14	(R)	
8	 VI	 –15	 48	 87	 16	(S)	
9	 VII	 –15	 67	 41	 60	(R)		
10	 VIII	 –15	 43	 >95	 22	(S)	
aReactions	 performed	 employing	2a	 (0.3	mmol),	1	 (0.6	mmol)	 in	 toluene	 [1M].	
bDetermined	 by	 1H-NMR.	 cDetermined	 by	 chiral	 GC.	 dIn	 parentheses,	 absolute	
configuration	of	the	major	enantiomer.	
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temperature	 (>95%	conversion,	 48	h,	 entry	3).	 Therefore,	we	
explored	 the	 behavior	 of	 diverse	 bifunctional	 H-bonding	
organocatalysts	 under	 these	 reaction	 conditions	 (entries	 4-
10).∫	 As	 observed	 for	 aryl-substituted	 α-keto	 esters,	 (R)-
BINAM-derived	 bis-urea	 III	 proved	 to	 be	 a	 superior	 catalyst	
than	its	bis-thiourea	analogue	II	(entry	5	vs	4),	affording	(R)-3a	
in	 full	 conversion	 and	 72%	 ee.	 The	 divergent	 stereochemical	
outcome	observed	for	these	two	catalysts	is	in	agreement	with	
different	 activation	 modes	 operating	 in	 each	 case	 and	 the	
major	 (R)	 absolute	 configuration	 provided	 by	 bis-urea	 III	 is	
consistent	 with	 the	 dual	 activation	 mode	 proposed	 for	 the	
aromatic	substrates	(see	model	in	Scheme	1).	Bifunctional	3,5-
bis(trifluoromethyl)phenyl-substituted	thioureas	bearing	cis-1-
amino-2-indanol	 (IV),	 trans-1,2-diaminocyclohexane	 (V)	 and	
tert-leucine	 (VI)	 chiral	 fragments	 afforded	 acceptable	
activation	 levels,	 albeit	with	 low	enantioselections	 (entries	 6-
8).	 The	 Jacobsen-type	 catalyst	VII	 showed	a	higher	 selectivity	
(60%	 ee)	 but	 lower	 activity	 (41%	 conversion,	 67	 h,	 entry	 9),	
probably	due	to	its	reduced	acidity	associated	with	the	lack	of	
electron-poor	aryl	groups.12	Finally,	multifunctional	D-glucose-
derived	 thiourea	 VIII	 was	 tested	 and	 the	 results	 revealed	 a	
slightly	superior	catalytic	activity,	reaching	full	conversion	in	a	
cleaner	 reaction,	 albeit	 in	 a	 low	 enantioselectivity	 (entry	 10).	
The	 performance	 exhibited	 by	 catalyst	VIII	 suggests	 that	 the	
carbohydrate	unit	might	serve	as	a	bulky-electron-withdrawing	
group,13	 increasing	 the	 acidity	 of	 thiourea	 and	 affording	
additional	 interactions	 with	mono-alkyl	 hydrazone	 1	 via	 NH–
O=C	bonding	(similar	to	that	proposed	in	the	BINAM-bis-urea)	
to	the	ester	carbonyl	groups.	Considering	this	hypothesis,	and	
the	 enormous	 modulation	 possibilities	 of	 carbohydrates	 as	
chiral	 scaffolds14	 we	 decided	 to	 synthesize	 and	 evaluate	 a	
small	 library	 of	 per-acylated	 hexosamine-derived	
organocatalysts	 placing	 a	 (thio)urea	 group	 at	 the	 C2	 position	
(Figure	2).	To	the	best	of	our	knowledge,	(thio)ureas	with	this	
alternative	design	have	not	been	evaluated	in	asymmetric	
	
Figure	2.	Hexosamine-derived	(thio)ureas	design.	
organocatalysis.15	These	compounds	were	synthesized	in	good	
overall	 yields	 according	 to	 the	 general	 strategy	 depicted	 in	
Scheme	 2.	 First,	 commercially	 available	 hexosamine	
hydrochlorides	 [D-glucosamine	 (6a)	 and	D-galactosamine	 (6b)]	
were	 efficiently	 converted	 into	 1,3,4,6-tetra-O-acyl-β-D-
glycosamine	 hydrochlorides	 8-10	 following	 a	 three	 step	
procedure:	 a)	 amine	 protection	 employing	p-anisaldehyde;	 b)	
standard	 esterifications;	 and	 c)	 removal	 of	 p-
methoxybenzylidene	group	with	HCl	in	acetone.	Subsequently,	
the	in	situ	generated	free	glycosamines	were	reacted	with	3,5-
bis-(trifluoromethyl)phenyl	 isocyanate	 or	 thiocyanate,	 to	
afford	the	corresponding	urea	 IX	and	thioureas	X-XIII	 in	good	
overall	yields	(71-95%).		
Next,	 the	 new	 set	 of	 saccharide-based	 organocatalysts	 were	
tested	 in	 the	model	 reaction	 (Table	 2).	 To	 our	 delight,	 D-per-
acetylated	glucosamine-derived	organocatalysts	IX	and	X	were	
more	 selective	 than	VIII	 (entries	 1-3),	 being	 thiourea	X	more	
active	than	urea	IX,	and	affording	(S)-3a	in	full	conversion	and	
a	higher	enantioselectivity	(58%	ee,	entry	3).	It	is	convenient	to	
remark	 that,	 in	 contrast	 with	 catalysts	 II/III,	 good	 H-bond	
acceptor	 functionalities	 (the	 carbonyl	 groups)	 are	available	 in	
both	cases,	so	that	the	better	performance	of	X	can	be	
	
Scheme	2.	Synthesis	of	hexosamine-based	(thio)ureas.	a)	p-anisaldehyde,	aq.	NaOH;	b)	O-Acylations;	c)	aq.	HCl,	acetone.	*3-step	(6→8)	yields.	d)	ArFNCX,	Et3N,	CH2Cl2.	
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Table	2.	Screening	of	saccharide-based	organocatalysts.a		
 
Entry	 Cat.	 Solvent	 Conv.	(%)b	 ee	(%)c	
1	 VIII	 Toluene	 >95	 22	
2	 IX	 Toluene	 65	 42	
3	 X	 Toluene	 >95	 58	
4	 XI	 Toluene	 >95	 8	
5	 XII	 Toluene	 85	 24	
6	 XIII	 Toluene	 78	 rac	
7	 X	 Trifluorotoluene	 86	 58	
8	 X	 TBME	 30	 34	
9	 X	 n-Hexane	 70	 48	
10	 X	 CH2Cl2	 60	 54	
aReactions	performed	employing	2a	 (0.3	mmol)	 and	1	 (0.6	mmol).	 bDetermined	
by	1H-NMR.	cDetermined	by	chiral	GC.	
explained	 by	 the	 higher	 acidity	 of	 the	 thiourea	 moiety.	
Notably,	 D-galactosamine	 derivative	 XI	 induced	 the	 lower	
selectivity	 within	 the	 series	 (entry	 4).	 The	 stereoelectronic	
influence	 by	 different	 acyl	 groups	 was	 analyzed	 employing	
catalyst	 XII	 (per-benzoylated)	 and	 XIII	 (per-pivaloylated).	
Acceptable	 levels	 of	 activation,	 albeit	 low	 enantioselectivies,	
were	observed	 in	both	cases	(entries	5	and	6).	Finally,	poorer	
conversions	 and/or	 enantioselectivities	 were	 observed	 in	
solvents	 such	 as	 trifluorotoluene	 (entry	 8),	 tert-butyl	 methyl	
ether	(TBME,	entry	8),	n-hexane	(entry	9)	or	CH2Cl2	(entry	10).	
Thus,	 the	model	 reaction	 revealed	 BINAM	bis-urea	 III	 and	 D-
glucosamine	 derivative	 X	 as	 the	 most	 selective	 and	 active	
organocatalysts,	 respectively.	 Consequently,	 the	 scope	 of	 the	
reaction	 with	 a	 range	 of	 alkyl-substituted	 α-keto	 esters	 was	
then	 explored	 employing	 both	 organocatalysts.	 The	 collected	
data	(Table	3)	indicates	that	the	expected	products	(R)-3	were	
obtained	with	acceptable	yields	(60-88%)	when	catalyst	III	was	
used,	although	the	enantioselectivities	were	highly	dependent	
on	the	alkyl	substituents	(entries	1,	3,	5,	7,	9	and	11),	dropping	
for	 those	α-keto	esters	bearing	 linear	alkyl	 chains	 [3a,	R	=	 iPr	
(72%	ee);	3b,	 R	=	Me	 (49%	ee);	3c,	 R	=	 nPr	 (16%	ee);	3d,	 R	=	
nHex	 (16%	 ee);	 3e,R	 =	 Bn	 (50%	 ee);	 3f,	 R	 =	 CH2CH2Ph	 (14%	
ee)].¶	 On	 the	 other	 hand,	 faster	 and	 cleaner	 reactions	
catalyzed	 by	 X	 afforded	 products	 (S)-3	 in	 good	 to	 excellent	
yields	(75-98%)	and	moderate	enantioselectivities	(50-64%	ee),	
without	 significant	 variations	 depending	 on	 the	 alkyl	 chain	
structures	(entries	2,	4,	6,	8,	10	and	12).	Substrate	2e	carrying	
a	benzyl	substituent	reacted	much	faster,	reaching	completion	
in	 shorter	 times	 (24	 h),	 even	 at	 –45	 °C.	 In	 this	 case,	 both	
organocatalysts	provided	similar	ee's	(above	50%	ee,	entries	9	
and	 10).	 As	 limitation,	 a	 poorer	 reactivity	 was	 observed	 for	
tBu-substituted	α-keto	ester	2g	 (entries	13	and	14).	Even	at	0	
°C	for	prolonged	reaction	times,	(S)-3g	was	obtained	with	20%	
yield	and	64%	ee	in	presence	of	catalyst	X.	
Table	3.	Organocatalytic	additions	of	1	to	alkyl-substituted	α-keto	esters	2.a	
 
Entry	 2	 R	 Cat.	 3	 Yield	(%)b	 ee	(%)	
1	 2a	 iPr	 III	 (R)-3a	 74	 c	72	
2	 2a	 iPr	 X	 (S)-3a	 98	 58c	
3	 2b	 Me	 III	 (R)-3b	 75	 49c	
4	 2b	 Me	 X	 (S)-3b	 85	 62c	
5	 2c	 n-Pr	 III	 (R)-3c	 62	 16d	
6	 2c	 n-Pr	 X	 (S)-3c	 85	 45d	
7	 2d	 n-C6H13	 III	 (R)-3d	 60	 16e	
8	 2d	 n-C6H13	 X	 (S)-3d	 90	 63e	
9f	 2e	 Bn	 III	 (R)-3e	 80	 50d	
10f	 2e	 Bn	 X	 (S)-3e	 88	 56d	
11	 2f	 Ph(CH2)2	 III	 (R)-3f	 88	 14e	
12	 2f	 Ph(CH2)2	 X	 (S)-3f	 86	 64e	
13g	 2g	 tBu	 III	 (R)-3g	 14	 42e	
14g	 2g	 tBu	 X	 (S)-3g	 20	 64e	
aReactions	performed	employing	2	(0.6	mmol),	1	(1.2	mmol)	for	48	h	(III)	or	43	h	
(X).	 bIsolated	 yield.	 cDetermined	 by	 chiral	 GC.	 dDetermined	 by	 chiral	 HPLC.	
eDetermined	by	chiral	HPLC	of	its	corresponding	azoxymethyl	alcohol	4.	fReaction	
performed	at	–45	°C	for	24	h.	gReaction	performed	at	0	°C	for	72	h.	
The	versatility	of	the	N-tert-butyldiazenylmethylene	group	is	in	
good	part	attributed	to	its	equivalence	with	the	formyl	group.	
Thus,	 representative	 azomethyl	 alcohols	 3c,e	 were	
transformed	 into	 aldehydes	 12c,e	 via	 a	 tautomerization–
hydrolysis	 sequence	 accomplished	 by	 simple	 treatment	 with	
HCl	 in	 a	 biphasic	 H2O/Et2O	 medium	 (Scheme	 3).	 Crude	
aldehydes	12	did	not	resist	chromatographic	purifications	but	
were	isolated	with	a	high	degree	of	purity	(>90%,	estimated	by	
1H-NMR).	These	 intermediates	were	treated	with	Bu4NBH4	to	
yield	diols	13c,e	in	satisfactory	overall	yields.		The	absolute	(S)	
configuration	 of	 adducts	3c,e	 (stereochemistry	 induced	 by	X)	
was	 determined	 by	 chemical	 correlation	 of	 diols	13c,e.16	 The	
absolute	 configuration	 of	 other	 adducts	 3	 and	 derivatives	
thereof	was	assigned	by	analogy	assuming	a	uniform	reaction	
pathway	[(S)	induced	by	X	and	(R)	induced	by	III].	
	
Scheme	3.	Synthesis	of	optically	active	diols	(S)-13.	
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Synthesis	of	azoxymethyl	alcohols	4	
The	azoxy-containing	natural	products17	constitute	a	small	but	
growing	family	of	compounds	with	varied	biological	activities,	
the	common	structural	feature	of	which	is	the	presence	of	an	
azoxy	 group	 (N=N→O).	 Compounds	 in	 this	 family	 include	 the	
antitumour	agent	valanimycin,	the	carcinogen	elaiomycin,	the	
antifungal	 agents	 maniwamycin	 A	 and	 azoxybacilin,	 and	 the	
nematocidal	 compounds	 jietacins	 A	 and	 B,	 among	 others	
(Figure	 3).	 The	 increasing	 interest	 in	 this	 class	 of	 bioactive	
compounds,	 however,	 contrasts	 with	 the	 lack	 of	 available	
reactions	 for	 the	 direct	 introduction	 of	 azoxy	 groups.	 In	 this	
context,	oxidation	of	diazenes	 is	a	 reasonably	straightforward	
methodology,	 although	 the	 control	 of	 regioselectivity	 usually	
appears	as	an	issue	to	overcome.18	Previous	studies	performed	
in	 our	 laboratories,10c,d	 however,	 revealed	 that	 the	 N-
oxidationtakes	 place	 selectively	 at	 the	 most	 hindered	 tert-	
butyl	 substituted	 nitrogen	 atom	 in	 similar	 derivatives.	
Therefore,	we	decided	to	explore	the	use	of	different	oxidizing	
reagents	 for	 the	 regioselective	 N-oxidation	 of	 compounds	 3	
leading	 to	azoxy	compunds	4	 (Table	4).	Azomethyl	alcohol	3a	
toluene/CH2Cl2	mixture	(full	conversion	in	4	hours)	or		
	
Figure	3.	Bioactive	molecules	containing	an	azoxy	moiety.	
magnesium	 monoperoxyphthalate	 (MMPP)	 in	 a	
toluene/MeOH	 mixture	 (full	 conversion	 in	 1	 hour).	 It	 was	
found	out	 that	 elimination	 of	 toluene	 after	 the	 addition	 step	
facilitates	the	isolation	of	product	4a	in	excellent	yield	(98%		
Table	4.	One-pot	synthesis	of	azoxymethyl	alcohols	4.a	
 
Entry	 2	 Cat.	 T	(°C)	 t	(h)b	 4	 Yield	(%)c	 ee	(%)d	
1	 2a	 X	 −15	 43	 (S)-4a	 98	 57	
2	 2b	 X	 −15	 43	 (S)-4b	 77	 61	
3	 2c	 X	 −15	 43	 (S)-4c	 78	 49	
4	 2d	 X	 −15	 43	 (S)-4d	 84	 63	
5	 2e	 X	 −45	 24	 (S)-4e	 88	 58	
6	 2f	 X	 −15	 43	 (S)-4f	 77	 64	
7e	 2g	 III	 −30	 48	 (R)-4h	 80	 89	
8f	 2h	 III	 −45	 7	 (R)-4i	 90	 88	
9	 2i	 III	 −45	 9	 (R)-4j	 83	 86	
10	 2j	 III	 −45	 6	 (R)-4k	 82	 90	
11	 2k	 III	 −30	 72	 (R)-4l	 79	 85	
aReactions	 performed	 employing	2	 (0.6	mmol),	1	 (1.2	mmol)	 and	Cat.	 (10	mol%)	 at	 the	 temperature	 and	 for	 the	 time	 indicated.	 bReaction	 time	 of	 the	 first	 step.	
cIsolated	yield.	dDetermined	by	chiral	HPLC.	
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overall,	 2-steps),	 with	 total	 regioselectivity	 and	 without	
racemization.	 Performing	 the	 addition	 with	 catalyst	 X	 in	
toluene	 at	 –15/–45	 °C,	 followed	 by	 the	 optimized	 oxidation	
protocol,	 alkyl-substituted	azoxymethyl	 alcohols	 (S)-4a-f	were	
synthesized	 in	 good	 overall	 yields	 (77-98%	 over	 2-steps)	 and	
moderate	 enantioselectivities	 (50-64%	 ee),	 consistent	 with	
those	measured	 in	 their	parent	azomethyl	 alcohols	3	 (entries	
1-6).	In	the	aromatic	series,	(R)-BINAM	bis-urea	III	was	used	at	
lower	temperatures	(–30/–45	°C)	for	the	first	step	to	yield	aryl-
/heteroaryl-substituted	 azoxymethyl	 alcohols	 (R)-4g-k	 with	
several	 substitution	patterns	 (entries	 7-11)	 in	high	 yields	 (79-
90%)	and	enantioselectivities	(85-90%	ee).	
Synthesis	of	α-hydroxy-β-amino	esters	5	
Azomethyl	alcohols	3	proved	to	be	also	suitable	precursors	for	
quaternary	α-hydroxy-β-amino	acids	(isoserines).	The	required	
transformation	of	the	N-tert-butyldiazenylmethylene	group	of	
3	 into	 the	 aminomethyl	 group	 in	 5	was	 accomplished	 via	 a	
one-pot	 tautomerization/hydrolysis/reductive	 amination	
sequence,	 as	 depicted	 in	 Scheme	 4.	 Treatment	 of	
enantiomerically	 enriched	 diazene	 (S)-3a,	 with	 HCl	 in	 a	
biphasic	H2O/Et2O	medium,	followed	by	simple	L–L	extractions	
afforded	crude	α-hydroxy	aldehyde	(S)-12a	with	a	high	degree	
of	 purity.	 Subsequent	 reductive	 amination	 using	 p-anisidine	
(PMPNH2)	and	sodium	cyanoborohydride	(NaCNBH3)	in	
	
Scheme	4.	Synthesis	of	α-hydroxy-β-amino	esters	5.	
Table	5.	Synthesis	of	α-hydroxy-β-amino	esters	5.a	
Entry	 2	 Cat.	 T	(°C)	 t	(h)b	 5	 Yield	(%)c	 ee	(%)d	
1	 2a	 X	 −15	 43	 (S)-5a	 49	 61	
2	 2c	 X	 −15	 43	 (S)-5c	 40	 55	
3	 2d	 X	 −15	 43	 (S)-5d	 50	 61	
4	 2e	 X	 −45	 24	 (S)-5e	 45	 51	
5	 2f	 X	 −15	 43	 (S)-5f	 41	 62	
6	 2h	 III	 −30	 48	 (R)-5h	 51	 90	
7	 2i	 III	 −45	 7	 (R)-5i	 46	 90	
8	 2j	 III	 −45	 9	 (R)-5j	 46	 84	
9	 2k	 III	 −45	 6	 (R)-5k	 44	 93	
10	 2l	 III	 −30	 72	 (R)-5l	 41	 84	
aReactions	performed	employing	2	(0.6	mmol),	1	(1.2	mmol)	and	Cat.	(10	mol%)	
at	 the	 temperature	and	 for	 the	 time	 indicated.	 bReaction	 time	of	 the	 first	 step.	
cIsolated	yield.	dDetermined	by	chiral	HPLC.	
CH2Cl2,
‡	 afforded	 (S)-5a	 in	 a	 satisfactory	 overall	 yield	 (49%,	 4	
steps)	 and	 enantioselectivity	 consistent	 with	 the	 azomethyl	
alcohol	precursor	(S)-3a	(entry	1,	Table	5).		
Employing	 organocatalysts	 X	 or	 III	 for	 the	 asymmetric	
functionalization	 of	 alkyl-	 or	 aryl-substituted	 α-keto	 esters	
followed	by	the	above	discussed	protocol	in	a	pseudo	one	pot	
fashion,	 gave	 the	 targeted	 α-hydroxy-β-amino	 esters	 5	 in	
satisfactory	 overall	 yields	 (41-51%)	 and	 moderate	 to	 good	
enantiomeric	excesses	(Table	5).	
Conclusions	
In	 summary,	 readily	available	per-acetylated	β-D-glucosamine	
thiourea	 X	 appears	 as	 a	 competent	 organocatalyst	 for	 the	
asymmetric	 nucleophilic	 addition	 of	 formaldehyde	 tert-butyl	
hydrazone	 1	 to	 α-keto	 esters	 2.	 Compared	 to	 previously	
established	 BINAM	 bis-urea	 III	 catalysts,	 these	 new	 family	 of	
bifunctional	 thioureas	 shows	 a	 fair	 catalytic	 activity	 and	 a	
complementary	 scope,	 enabling	 the	 obtention	 of	 aliphatic	
tertiary	 azomethyl	 alcohols	 3	with	 high	 yields	 and	moderate	
enantioselectivities.	 Both	 aromatic-	 and	 aliphatic-substituted	
products	 3	 have	 been	 employed	 as	 key	 precursors	 for	 the	
synthesis	 of	 biologically	 relevant	 azoxy	 compounds	 4	 and	α-
hydroxy-β-amino	esters	5.	
Experimental	
Spectra	were	recorded	at	[1H	NMR	(300,	400	or	500	MHz);	13C	NMR	
(75,	100	or	125	MHz);	19F	NMR	(470.6	MHz)]	with	the	solvent	peak	
used	 as	 the	 internal	 reference	 (7.26	 and	 77.0	 ppm	 for	 1H	 and	 13C	
respectively).	Column	chromatography	was	performed	on	silica	gel	
(Merck	 Kieselgel	 60).	 Analytical	 TLC	was	 performed	 on	 aluminium	
backed	 plates	 (1.5	 ×	 5	 cm)	 pre-coated	 (0.25	 mm)	 with	 silica	 gel	
(Merck,	 Silica	 Gel	 60	 F254).	 Compounds	 were	 visualized	 by	
exposure	to	UV	light	or	by	dipping	the	plates	in	solutions	of	KMnO4,	
vainilline	 or	 phosphomolibdic	 acid	 stains	 followed	 by	 heating.	
Melting	points	were	recorded	in	a	metal	block	and	are	uncorrected.	
Unless	otherwise	noted,	analytical	grade	solvents	and	commercially	
available	 reagents	 were	 used	 without	 further	 purification.	
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not	 commercially	 available	 α-keto	 esters	 222	 were	 synthesized	
according	to	literature	procedures.	
Synthesis	of	saccharide-based	organocatalysts	
VIII:	 3,5-Bis(trifluoromethyl)phenyl	 isothiocyanate	 (151	 µL,	 0.8	
mmol)	 was	 added	 to	 a	 solution	 of	 2,3,4,6-tetra-O-acetyl-β-D-
glucopyranosylamine23	 (256	mg,	 0.7	mmol)	 in	 CH2Cl2	 (10	mL).	 The	
reaction	 mixture	 was	 stirred	 for	 20	 h	 at	 rt	 and	 the	 solvent	 was	
removed	 in	 vacuo.	 Flash	 chromatography	 (Et2O/n-hexane/CH2Cl2	
5:1:1)	afforded	VIII	(243	mg,	56%)	as	a	white	solid.	M.P.	=	68-70	°C.	
1H	NMR	(500	MHz,	CDCl3)	δ	8.62	 (s,	1H),	7.94	 (s,	2H),	7.61	 (s,	1H),	
7.03	(d,	J	=	10.0	Hz,	1H),	5.73	(t,	J	=	5.0	Hz,	1H),	5.38	(t,	J	=	10.0	Hz,	
1H),	5.21	(t,	J	=	10.0	Hz,	1H),	5.09	(t,	J	=	10.0	Hz,	1H),	4.71	(dd,	J	=	
10.0,	5.0	Hz,	1H),	3.99	(d,	J	=	10.0	Hz,	1H),	3.93-3.89	(m,	1H),	2.09	(s,	
3H),	 2.06	 (s,	 6H),	 2.03	 (s,	 3H).	 13C	NMR	 (125	MHz,	CDCl3)	δ	182.4,	
172.3,	171.1,	170.2,	169.5,	139.1,	131.6	(q,	J	=	34.0	Hz),	124.3	(q,	J	=	
262.0	Hz),	 124.2,	119.0	 (t,	 J	=	2.5	Hz),	 82.8,	75.5,	73.7,	70.9,	68.7,	
62.5,	 21.1,	 20.7,	 20.6,	 20.5.	 HRMS:	 m/z	 calculated	 for	
[C23H24F6N2O9SNa]
+:	 641.0999;	 found:	 641.1002.	 [α]D
20	 =	 +22.6	 (c	
1.0,	CHCl3).	
General	procedure	for	the	synthesis	of	hexosamine-derived	amine	
hydrochlorides	8-10	
p-Anisaldehyde	(2.8	mL,	36.6	mmol)	was	added	to	a	solution	of	D-
hexosamine	hydrochloride	6a,b	 (5	g,	23.2	mmol)	 in	NaOH	aq.	(1M,	
25	mL)	at	0	°C.	The	mixture	was	stirred	 for	 	 	3̴	h	until	a	crystalline	
solid	 was	 formed,	 which	 was	 then	 filtered	 and	 washed	 with	 cold	
H2O	 (2x50	mL),	 EtOH	 (50	mL)	 and	 Et2O	 (50	mL).	 The	 crude	 imine	
intermediates	 were	 directly	 subjected	 to	O-acylation	 reactions	 to	
afford	 per-O-acylated	 imines	 7.	 O-acetylation:	 Acetic	 anhydride	
(16.8	mL,	 118	mmol)	was	 added	 to	 a	 solution	 of	 the	 crude	 imine	
(5.9	 g,	 19.8	 mmol)	 in	 pyridine	 (17.6	 mL,	 218	 mmol)	 at	 0	 °C.	 The	
reaction	mixture	was	allowed	to	reach	rt	and	stirred	for	 	 	 ̴24	h.	An	
ice-H2O	 (50	 mL)	 mixture	 was	 added	 and	 the	 resulting	 solid	 was	
filtered,	washed	with	cold	H2O	(2	×	30	mL)	and	recrystallized	from	
EtOH.	 O-benzoylation:	 Et3N	 (30.4	 mL,	 217.8	 mmol)	 and	 benzoyl	
chloride	 (20.7	 mL,	 178.2	 mmol)	 were	 added	 to	 a	 solution	 of	 the	
crude	 imine	 (5.9	 g,	 19.8	 mmol)	 in	 CH2Cl2	 (150	 mL)	 at	 0	 °C.	 The	
reaction	 mixture	 was	 allowed	 to	 warm	 to	 rt,	 stirred	 for	 	 	 ̴24	 h,	
washed	with	NaHCO3	(4	×	30	mL)	and	concentrated	to	dryness.	O-
pivaloylation:	 Et3N	 (30.4	 mL,	 217.8	 mmol)	 and	 pivaloyl	 chloride	
(26.8	mL,	218	mmol)	were	added	 to	a	 solution	of	 the	crude	 imine	
(5.9	g,	19.8	mmol)	in	CH2Cl2	(150	mL)	at	60	°C.	The	reaction	mixture	
was	 stirred	 for	 	 	 ̴24	 h,	 washed	 with	 NaHCO3	 (4	 ×	 30	 mL)	 and	
concentrated		to	dryness.	
Imine	 hydrolysis:	 HCl	 (5M,	 5	mL)	was	 added	 to	 a	 solution	 of	 per-
acylated	 imine	 7	 (17.8	 mmol)	 in	 acetone	 (40	 mL)	 at	 0	 °C.	 The	
reaction	 was	 stirred	 for	 2	 h,	 concentrated	 to	 dryness	 and	 the	
resulting	residue	was	washed	with	cold	Et2O	(2x50	mL)	to	afford	O-
acyl	amine	hydrochlorides	8-10.	
8a:	White	solid	(6.4	g,	72%).	Characterization	data	 is	 in	agreement	
with	a	literature	report.24		
8b:	White	solid	(5.7	g,	64%).	Characterization	data	 is	 in	agreement	
with	a	literature	report.25	
9a:	White	solid	(8.9	g,	61%),	M.P.	=	202-204	°C.	1H	NMR	(500	MHz,	
CD3OD)	δ	8.18	(dd,	J	=	8.1,	1.0	Hz,	2H),	7.98	(td,	J	=	8.3,	1.4	Hz,	4H),	
7.85	(dd,	J	=	7.9,	1.0	Hz,	2H),	7.71	(t,	J	=	10.0	Hz,	1H),	7.60-7.52	(m,	
6H),	7.42	(td,	J	=	8.0,	2.1	Hz,	4H),	7.36	(t,	J	=	8.2	Hz,	2H),	6.38	(d,	J	=	
10.0	Hz,	1H),	5.93	(t,	J	=	10.0	Hz,	1H),	5.80	(t,	J	=	10.0	Hz,	1H),	4.65-
4.64	(m,	1H),	4.49-4.40	(m,	2H),	4.17	(dd,	J	=	10.2,	8.9	Hz,	1H).	13C	
NMR	 (125	MHz,	 CDCl3)	 δ	 167.6,	 167.4,	 166.7,	 165.7,	 135.5,	 135.0,	
134.9,	134.5,	131.4,	131.0,	130.7,	129.9,	129.6,	129.6,	129.5,	92.8,	
74.2,	 73.2,	 70.4,	 63.6,	 54.8.	 HRMS:	 m/z	 calculated	 for	
[C34H30NO9Cl]
+:	596.6100;	found:	596.6110.		
10a:	White	solid	(6.9	g,	54%),	M.P.	=	205-207	°C.	1H	NMR	(500	MHz,	
CD3OD)	δ	5.93	(d,	J	=	10.0	Hz,	1H),	5.45	(t,	J	=	10.0	Hz,	1H),	5.18	(t,	J	
=	10.0	Hz,	1H),	4.14	(d,	J	=	5.0	Hz,	2H),	4.08-4.04	(m,	1H),	3.69	(t,	J	=	
5.0	Hz,	1H),	1.27	(s,	9H),	1.22	(s,	9H),	1.19	(s,	9H),	1.18	(s,	9H).	13C	
NMR	 (125	MHz,	 CD3OD)	 δ	 179.3,	 178.8,	 177.9,	 177.4,	 92.0,	 74.0,	
72.7,	69.3,	62.5,	54.4,	40.1,	40.0,	39.9,	39.8,	27.5,	27.4,	27.2.	HRMS:	
m/z	calculated	for	[C26H46NO9Cl]
+:	516.6525;	found:	516.6529.		
General	procedure	for	the	synthesis	of	hexosamine-derived	
(thio)ureas	IX-XIII		
Et3N	 (0.7	 mL,	 5.3	 mmol)	 and	 3,5-bis(trifluoromethyl)phenyl	
isocyanate	or	isothiocyanate	(2.4	mmol)	were	sequentially	added	to	
a	solution	of	amine	hydrochloride	8-10	(2.2	mmol)	in	CH2Cl2	(10	mL)	
at	room	temperature.	Reaction	mixture	was	stirred	for	24	h.	Solvent	
was	removed	 in	vacuo	and	the	obtained	solid	was	purified	by	flash	
chromatography	(Et2O/n-hexane/CH2Cl2	5:1:1)	to	afford	the	desired	
(thio)urea.	
IX:	White	 solid	 (981	 mg,	 74%),	 M.P.	 =	 194-196	 °C.	 1H	 NMR	 (400	
MHz,	CDCl3)	δ	7.82	(s,	2H),	7.50	(s,	2H),	5.87	(d,	J	=	8.6	Hz,	1H),	5.42	
(d,	 J	=	8.6	Hz,	1H),	5.31	 (t,	 J	=	9.8	Hz,	1H),	5.16	 (t,	 J	=	9.8	Hz,	1H),	
4.30	(dd,	J	=	12.5,	4.0	Hz,	1H),	4.19-4.15	(m,	2H),	3.97-3.93	(m,	1H),	
2.15	 (s,	 3H),	 2.10	 (s,	 3H),	 2.08	 (s,	 3H),	 2.06	 (s,	 3H).	 13C	NMR	 (100	
MHz,	CDCl3)	δ	171.8,	170.8,	169.8,	169.4,	153.9,	140.1,	132.2	(q,	J	=	
33.1	Hz),	120.9	(q,	J	=	271.2	Hz),	118.6,	116.3,	92.8,	72.7,	72.6,	68.0,	
61.7,	 54.2,	 20.9,	 20.7,	 20.6,	 20.5.	 HRMS:	 m/z	 calculated	 for	
[C23H24F6N2O10Na]
+:	625.4310;	found:	625.4320.	[α]D
20	=	+9.2	(c	1.0,	
CHCl3).	
X:	White	 solid	 (1.1	 g,	 84%),	 M.P.	 =	 64-66	 °C.	 1H	 NMR	 (500	MHz,	
CDCl3)	δ	8.40	(s,	1H),	7.91	(s,	2H),	7.69	(s,	1H),	6.32	(br	s,	1H),	5.81	
(d,	J	 	=	8.5	Hz,	1H),	5.26-5.22	(m,	2H),	5.12	(br	s,	1H),	4.28	(dd,	J	 	=	
12.5,	4.5	Hz,	1H),	4.16	(dd,	J	 	=	12.5,	2.5	Hz,	1H),	3.89-3.86	(m,	1H),	
2.15	 (s,	 3H),	 2.10	 (s,	 3H),	 2.07	 (s,	 3H),	 2.04	 (s,	 3H).	 13C	NMR	 (125	
MHz,	CDCl3)	δ	182.1,	171.8,	170.8,	169.7,	169.4,	139.2,	132.5	(q,	J	=	
33.3	Hz),	124.1	(q,	J	=	271.3	Hz),	122.9,	119.4,	92.9,	72.9,	72.8,	67.8,	
61.7,	 57.7,	 20.9,	 20.7,	 20.7,	 20.5.	 HRMS:	 m/z	 calculated	 for	
[C23H24F6N2O9SNa]
+:	641.1004;	found:	641.1015.	[α]D
20	=	−1.6	(c	1.0,	
CHCl3).	
XI:	White	solid	(966	mg,	71%),	M.P.	=	68-70	°C.	1H	NMR	(500	MHz,	
CDCl3)	δ	8.34	(s,	1H),	7.91	(s,	2H),	7.68	(s,	1H),	6.52	(br	s,	1H),	5.83	
(d,	 J	=	8.1	Hz,	1H),	5.42	(s,	1H),	5.22	(d,	 J	=	9.0	Hz,	1H),	5.08	(br	s,	
1H),	4.20-4.15	(m,	3H),	2.21	(s,	3H),	2.16	(s,	3H),	2.05	(s,	3H),	2.03	(s,	
3H).	13C	NMR	(125	MHz,	CDCl3)	δ	182.5,	171.4,	170.9,	170.6,	169.9,	
139.2,	132.7	 (q,	 J	=	34.0	Hz),	124.1	 (q,	 J	=	244.0	Hz),	123.9,	119.5,	
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93.5,	72.2,	71.0,	66.6,	61.6,	55.0,	21.1,	20.9,	20.8,	20.8.	HRMS:	m/z	
calculated	 for	 [C23H24F6N2O9SNa]
+:	 641.0999;	 found:	 641.0989.	
[α]D
20	=	+19.8	(c	1.0,	CHCl3).	
XII:	White	 solid	 (1.6	 g,	 84%),	M.P.	 =	 75-77	 °C.	 1H	NMR	 (400	MHz,	
CDCl3)	δ	8.17	(d,	J	=	8.0	Hz,	2H),	8.09	(br	s,	1H),	8.01	(d,	J	=	8.0	Hz,	
2H),	7.91	(d,	J	=	8.0	Hz,	2H),	7.84	(d,	J	=	8.0	Hz,	2H),	7.58-7.50	(m,	
6H),	 7.43-7.32	 (m,	8H),	 7.22-7.10	 (m,	1H),	 6.89	 (d,	 J	 =	 7.1	Hz,	 1H),	
6.35	(d,	J	=	8.0	Hz,	1H),	5.87-5.78	(m,	2H),	5.67	(br	s,	1H),	4.71	(d,	J	=	
8.0	Hz,	1H),	4.60-4.40	(m,	2H).	 13C	NMR	(100	MHz,	CDCl3)	δ	182.3,	
167.9,	166.4,	165.6,	165.5,	139.2,	134.3,	133.8,	133.4,	132.3	(q,	J	=	
26.7	 Hz),	 130.7,	 130.2,	 130.0,	 129.8,	 129.6,	 128.8,	 128.8,	 128.6,	
128.6,	128.3,	124.7,	123.0	(q,	J	=	272.1	Hz),	119.2,	93.9,	73.8,	73.3,	
69.7,	 63.1,	 58.1.	 HRMS:	 m/z	 calculated	 for	 [C43H32F6N2O9SNa]
+:	
889.1625;	found:	889.1611.	[α]D
20	=	–28.5	(c	0.5,	CHCl3).	
XIII:	White	 solid	 (1.6	 g,	 95%),	M.P.	 =	80-82	 °C.	 1H	NMR	 (300	MHz,	
CDCl3)	δ	8.27	(br	s,	1H),	7.79	(s,	2H),	7.72	(s,	1H),	6.4	(br	s,	1H),	5.73	
(d,	J	=	8.4	Hz,	1H),	5.27	(d,	J	=	9.1	Hz,	2H),	4.17	(d,	J	=	3.0	Hz,	2H),	
3.89-3.86	(m,	1H),	2.04	(s,	1H),	1.22	(s,	9H),	1.22	(s,	9H),	1.17	(s,	9H),	
1.15	(s,	9H).	13C	NMR	(75	MHz,	CDCl3)	δ	182.1,	180.1,	178.3,	176.5,	
139.1,	133.3	 (q,	 J	=	33.0	Hz),	124.9,	122.8	 (q,	 J	=	271.0	Hz),	120.0,	
93.2,	73.5,	72.7,	67.4,	61.8,	57.3,	39.3,	39.1,	39.1,	39.0,	27.3,	27.2,	
27.2,	27.0.	HRMS:	m/z	calculated	for	[C35H48F6N2O9SNa]
+:	809.2877;	
found:	809.2866.	[α]D
20	=	+13.6	(c	1.0,	CHCl3).	
General	procedure	for	the	catalytic	enantioselective	reactions	of	
tert-butyl	hydrazone	1	with	α-keto	esters	2.	
Formaldehyde	tert-butyl	hydrazone	1	(134	μL,	1.2	mmol)	was	added	
to	a	solution	of	α-keto	ester	2	(0.6	mmol)	and	catalyst	X	or	III	(0.06	
mmol)	in	toluene	(0.6	mL)	at	the	specified	temperature	(Tables	3-5).	
The	 mixture	 was	 stirred	 for	 the	 time	 specified	 (TLC	 monitoring).	
Solvent	 was	 removed	 in	 vacuo.	 Flash	 chromatography	
(Toluene/EtOAc)	afforded	the	corresponding	azomethyl	alcohols	3.	
Ethyl	 (S,E)-2-[(tert-butyldiazenyl)methyl]-2-hydroxy-3-methyl	
butanoate	 [(S)-3a]:	 Yelow	 oil	 (144	 mg,	 98%);	 1H	 NMR	 (400	 MHz,	
CDCl3)	δ	4.23	(q,	J	=	6.8	Hz,	2H),	4.11	(d,	J	=	12.8	Hz,	1H),	3.85	(d,	J	=	
12.8	Hz,	1H),	3.29	(s,	1H),	2.18-2.11	(m,	1H),	1.28	(t,	J	=	6.8	Hz,	3H),	
1.15	 (s,	 9	H),	1.02	 (d,	 J	=	6.8	Hz,	3H,),	 0.91	 (d,	 J	 =	6.8	Hz,	3H).	 13C	
NMR	 (100	MHz,	 CDCl3)	 δ	 175.2,	 78.8,	 73.7,	 67.7,	 61.7,	 34.0,	 26.6,	
17.0,	16.1,	14.1.	HRMS:	m/z	calculated	for	[C12H24N2O3]
+:	244.3314;	
found:	 244.3318.	 The	 enantiomeric	 excess	was	 determined	 by	GC	
[Chrompack	CP7500,	 cyclodextrin-β,	 225	m	 x	 0.25	mm	x	 0.25	μm,	
He	as	mobile	phase,	 τmajor	=	14.3	min,	 τminor	=	13.8	min,	 (58%	ee)];	
[α]D
20	=	+17.8	(c	0.8,	CH2Cl2).	
Ethyl	 (R,E)-2-[(tert-butyldiazenyl)methyl]-2-hydroxy-3-methyl	
butanoate	 [(R)-3a]:	Yelow	oil	 (109	mg,	74%).	 [α]D
20	 =	+21.1	 (c	 1.0,	
CH2Cl2,	72%	ee).	
Ethyl	 (S,E)-3-(tert-butyldiazenyl)-2-hydroxy-2-methylpropanoate	
[(S)-3b]:	Yelow	oil	(110	mg,	85%);	1H	NMR	(400	MHz,	CDCl3)	δ	4.25-
4.19	(m,	2H),	4.17	(d,	J	=	13.2	Hz,	1H),	3.83	(d,	J	=	13.2	Hz,	1H),	3.46	
(s,	1H),	1.52	(s,	3	H),	1.28	(t,	J	=	7.2	Hz,	3H),	1.17	(s,	9	H).	13C	NMR	
(100	MHz,	 CDCl3)	 δ	 175.3,	 77.1,	 75.2,	 73.8,	 61.7,	 26.6,	 23.9,	 14.1.	
HRMS:	 m/z	 calculated	 for	 [C10H20N2O3]
+:	 216.1474;	 found:	
216.1468.	 The	 enantiomeric	 excess	 was	 determined	 by	 GC	
[Chrompack	CP7500,	 cyclodextrin-β,	 225	m	 x	 0.25	mm	x	 0.25	μm,	
He	as	mobile	phase,	τmajor	=	17.3	min,	 τminor	=	17.1	min,	 (62%	ee)];	
[α]D
20	=	–5.8	(c	1.0,	CH2Cl2).	
Ethyl	 (S,E)-2-[(tert-butyldiazenyl)methyl]-2-hydroxypentanoate	 [(S)-
3c]:	Yelow	oil	(124	mg,	85%);	1H	NMR	(300	MHz,	CDCl3)	δ	4.25-4.15	
(m,	2H),	4.10	(d,	J	=	13.0	Hz,	1H),	3.78	(d,	J	=	13.0	Hz,	1H),	3.39	(s,	
1H),	1.84-1.46	(m,	4H),	1.25	(t,	J	=	7.0	Hz,	3H),	1.13	(s,	9H),	0.90	(t,	J	
=	7.0	Hz,	3H).	 13C	NMR	(125	MHz,	CDCl3)	δ	175.0,	76.6,	75.0,	67.7,	
61.6,	 39.4,	 26.7,	 16.4,	 14.2,	 14.1.	 HRMS:	 m/z	 calculated	 for	
[C12H25N2O3]
+:	245.1860;	found:	245.1862.	The	enantiomeric	excess	
was	determined	by	HPLC	using	a	Chiralpak	AD-H	column	[hexane/i-
PrOH	 (98:2)];	 flow	 rate	1	mL/min;	 τmajor	 =	6.7	min,	 τminor	 =	5.6	min	
(45%	ee);	[α]D
20	=	+23.0	(c	0.6,	CHCl3).	
Ethyl	 (S,E)-2-[(tert-butyldiazenyl)methyl]-2-hydroxyoctanoate	 [(S)-
3d]:	Yelow	oil	(155	mg,	90%);	1H	NMR	(400	MHz,	CDCl3)	δ	4.23	(q,	J	
=	7.2	Hz,	2H),	4.13	(d,	J	=	13.2	Hz,	1H),	3.80	(d,	J	=	13.2	Hz,	1H),	3.39	
(s,	1H),	1.86-1.71	(m,	2H),	1.56-1.49	(m,	2H),	1.30-1.26	(m,	6H),	1.28	
(t,	J	=	6.8	Hz,	3H),	1.16	(s,	9H),	0.87	(t,	J	=	6.4	Hz,	3H).	13C	NMR	(100	
MHz,	 CDCl3)	 δ	 175.3,	 77.4,	 75.3,	 68.0,	 61.9,	 37.4,	 31.8,	 29.5,	 26.9,	
23.1,	 22.7,	 14.4,	 14.2.	 HRMS:	m/z	 calculated	 for	 [C15H30N2O3Na]
+:	
309.2149;	 found:	 309.2142.	 The	 enantiomeric	 excess	 was	
determined	by	HPLC	of	 its	 corresponding	 azoxymethyl	 alcohol	 (S)-
4d;	[α]D
20	=	+5.9	(c	1.0,	CHCl3,	63%	ee).	
Ethyl	 (S,E)-2-benzyl-3-(tert-butyldiazenyl)-2-hydroxypropanoate	
[(S)-3e]:	Yellow	oil	(154	mg,	88%):	1H	NMR	(300	MHz,	CDCl3)	δ	7.23-
7.13	(m,	5H),	4.21	(d,	J	=	13.2	Hz,	1H),	4.10	(qd,	J	=	7.1,	2.9	Hz,	2H),	
3.77	(d,	J	=	13.2	Hz,	1H),	3.09	(d,	J	=	13.5	Hz,	1H),	3.01	(d,	J	=	13.5	
Hz,	 1H),	 1.18	 (t,	 J	 =	 7.1	 Hz,	 3H),	 1.09	 (s,	 9H).	 13C	 NMR	 (75	MHz,	
CDCl3)	 δ	 174.2,	 135.2,	 130.4,	 128.1,	 127.0,	 77.1,	 74.6,	 68.0,	 61.9,	
43.4,	26.8,	14.2.	HRMS:	m/z	calculated	for	[C16H25O3N2]
+:	293.1860;	
found:	293.1851.	The	enantiomeric	excess	was	determined	by	HPLC	
using	 a	 Chiralpak	 OJ-H	 column	 [hexane:iPrOH	 (98:2)];	 flow	 rate	 1	
mL/min;	 30	 °C,	 τmajor	 =	 6.5	min,	 τminor	 =	 7.2	min	 (56%	ee);	 [α]D
27	 =	
−4.83		(c	0.4,	CHCl3).	
Ethyl	 (S,E)-2-[(tert-butyldiazenyl)methyl]-2-hydroxy-4-phenyl	
butanoate	 [(S)-3f]:	 Yelow	 oil	 (158	 mg,	 86%);	 1H	 NMR	 (400	 MHz,	
CDCl3)	δ	7.28	 (m,	3H),	7.19	 (d,	 J	 =	7.2	Hz,	2H),	4.23	 (q,	 J	 =	7.2	Hz,	
2H),	4.17	 (d,	 J	=	13.2	Hz,	1H),	4.01	 (br	 s,	1H),	3.80	 (d,	 J	=	13.2	Hz,	
1H),	2.94-2.85	(m,	1H),	2.62-2.51	(m,	1H),	2.22-2.08	(m,	2H),	1.29	(t,	
J	 =	 7.2	 Hz,	 3H),	 1.17	 (s,	 9H).	 13C	 NMR	 (100	MHz,	 CDCl3)	 δ	 175.0,	
141.4,	 128.6,	 128.4,	 76.4,	 75.1,	 68.0,	 61.9,	 39.0,	 29.5,	 26.8,	 14.3.	
HRMS:	 m/z	 calculated	 for	 [C17H26N2O3Na]
+:	 329.1836;	 found:	
329.1829.	The	enantiomeric	excess	was	determined	by	HPLC	of	 its	
corresponding	 azoxymethyl	 alcohol	 (S)-4f;	 [α]D
20	 =	 +4.7	 (c	 1.0,	
CHCl3,	64%	ee).	
Ethyl	 (S,E)-2-[(tert-butyldiazenyl)methyl]-2-hydroxy-3,3-dimethyl	
butanoate	 [(S)-3g]:	 Yelow	 oil	 (31	 mg,	 20%);	 1H	 NMR	 (400	 MHz,	
CDCl3)	δ	4.32	(d,	J	=	13.2	Hz,	1H),	4.31-4.22	(m,	2H),	3.77	(d,	J	=	13.1	
Hz,	1H),	3.46	(s,	1H),	1.30	(t,	J	=	7.2	Hz,	3H),	1.14	(s,	9H),	1.06	(s,	9H).	
13C	NMR	(100	MHz,	CDCl3)	δ	175.1,	81.0,	70.9,	67.8,	61.7,	37.2,	26.8,	
25.7,	 14.3.	 HRMS:	 m/z	 calculated	 for	 [C13H27N2O3]
+:	 259.2016;	
found:	259.2010.	The	enantiomeric	excess	was	determined	by	HPLC	
of	 its	 corresponding	 azoxymethyl	 alcohol	 (S)-4g	 using	 a	 Chiralpak	
AD-H	column	[hexane/i-PrOH	(80:20)];	 flow	rate	1	mL/min;	τmajor	=	
4.5	min,	τminor	=	4.1	min	(64%	ee);	[α]D
20	=	+2.9	(c	0.7,	CHCl3).	
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General	procedure	for	the	synthesis	of	azoxymethyl	alcohols	4.	
Following	 the	 general	 procedure	 for	 the	 catalytic	 enantioselective	
reactions	 of	 hydrazone	 1	 (1.2	 mmol)	 with	 α-keto	 esters	 2	 (0.6	
mmol).	 After	 consumption	 of	 starting	 material,	 the	 solvent	 was	
removed	 in	 vacuo	 and	 the	 residue	was	dissolved	 in	MeOH	 (2	mL),	
cooled	 to	 0	 °C,	 and	 MMPP	 (1.48	 g,	 5	 equiv.)	 was	 added.	 The	
reaction	 mixture	 was	 stirred	 until	 consumption	 of	 the	 azomethyl	
alcohol	3	(tlc	monitoring,	2-3	h.),	diluted	with	H2O	(5	mL),	extracted	
with	 CH2Cl2	 (3	 ×	 10	 mL),	 dried	 over	 Na2SO4	 and	 concentrated	 in	
vacuo.	The	resulting	residue	was	purified	by	flash	chromatography	
(Toluene/EtOAc)	to	afford	azoxymethyl	alcohol	4.		
[(S)-4a]:	Yellow	oil	(154	mg,	98%).	1H	NMR	(400	MHz,	CDCl3)	δ	4.22-
4.20	(m,	2H),	3.63	(d,	J	=	17.0	Hz,	1H),	3.59	(d,	J	=	17.0	Hz,	1H),	3.36	
(s,	1H),	2.10-2.07	(m,	1H),	1.49	(s,	9H),	1.24	(t,	J	=	6.8	Hz,	3H),	1.00	
(d,	J	=	6.8	Hz,	3H),	0.88	(d,	J	=	6.8	Hz,	3H).	13C	NMR	(100	MHz,	CDCl3)	
δ	175.5,	78.6,	76.6,	61.7,	58.8,	33.8,	28.2,	17.2,	16.1,	14.3.	HRMS:	
m/z	calculated	for	[C12H24N2O4Na]
+:	283.1628;	found:	283.1623.	The	
enantiomeric	excess	was	determined	by	HPLC	using	a	Chiralpak	AD-
H	column	[hexane/i-PrOH	(98:2)];	 flow	rate	1	mL/min;	τmajor	=	10.4	
min,	τminor	=	9.9	min	(57%	ee);	[α]D
20	=	+7.5	(c	1.0,	CHCl3).	
[(S)-4b]:	White	 solid	 (108	mg,	77%),	M.P.:	 	97-99	°C.	 1H	NMR	 (500	
MHz,	CDCl3)	δ	4.24-4.13	(m,	2H),	3.64	(d,	J	=	15.0	Hz,	1H,),	3.49	(d,	J	
=	15.0	Hz,	1H),	3.44	(s,	1H),	1.48	(s,	9H),	1.46	(s,	3H),	1.22	(t,	J	=	5.0	
Hz,	 3H).13C	NMR	 (125	MHz,	 CDCl3)	 δ	 175.3,	 76.6,	 73.3,	 61.7,	 60.5,	
28.1,	 23.7,	 14.1.	 HRMS:	 m/z	 calculated	 for	 [C10H21N2O4Na]
+:	
255.1315;	 found:	 255.1311.	 The	 enantiomeric	 excess	 was	
determined	 by	 HPLC	 using	 a	 Chiralpak	 OJ	 column	 [hexane/i-PrOH	
(98:2)];	flow	rate	1	mL/min;	τmajor	=	11.5	min,	τminor	=	13.5	min	(61%	
ee);	[α]D
20	=	–3.5	(c	0.5,	CHCl3).	
[(S)-4c]:	Yellow	oil	(122	mg,	78%).	1H	NMR	(300	MHz,	CDCl3)	δ	4.27-
4.15	(m,	2H),	3.72	(d,	J	=	17.0	Hz,	1H),	3.61	(d,	J	=	17.0	Hz,	1H),	3.43	
(s,	1H),	1.79-1.72	(m,	2H),	1.60-1.53	(m,	2H),	1.50	(s,	9H),	1.25	(t,	J	=	
7.0	 Hz,	 3H),	 0.92	 (t,	 J	=	 7.3	 Hz,	 3H).	 13C	 NMR	 (125	MHz,	 CDCl3)	 δ	
175.2,	 76.3,	 61.7,	 60.1,	 39.1,	 28.2,	 16.6,	 14.3,	 14.1.	 HRMS:	 m/z	
calculated	 for	 [C12H24N2O4Na]:	 283.1628;	 found:	 283.1622.	 The	
enantiomeric	excess	was	determined	by	HPLC	using	a	Chiralpak	AD-
H	column	[hexane/i-PrOH	(98:2)];	 flow	rate	1	mL/min;	τmajor	=	15.1	
min,	τminor	=	12.0	min	(49%	ee);	[α]D
20	=	+15.5	(c	0.5,	CHCl3).	
[(S)-4d]:	Yellow	oil	(152	mg,	84%).	1H	NMR	(400	MHz,	CDCl3)	δ	4.23-
4.12	(m,	2H),	3.60	(d,	J	=	18.0	Hz,	1H),	3.49	(d,	J	=	18.0	Hz,	1H),	3.41	
(s,	1H),	1.73-1.69	(m,	2H),	1.56-1.49	(m,	2H),	1.47	(s,	9H),	1.27-1.19	
(m,	9H),	0.83	(t,	J	=	5.6	Hz,	3H).	13C	NMR	(100	MHz,	CDCl3)	δ	175.2,	
76.6,	76.3,	61.7,	60.1,	36.9,	31.6,	29.3,	28.1,	23.1,	22.5,	13.9,	14.3.	
HRMS:	 m/z	 calculated	 for	 [C15H30N2O4Na]
+:	 325.2098;	 found:	
325.2091.	The	enantiomeric	excess	was	determined	by	HPLC	using	a	
Chiralpak	 AD-H	 column	 [hexane/i-PrOH	 (80:20)];	 flow	 rate	 1	
mL/min;	τmajor	=	5.0	min,	τminor	=	4.3	min	 (63%	ee);	 [α]D
20	=	+6.2	 (c	
1.0,	CHCl3).	
[(S)-4e]:	Yellowish	 oil	 (163	mg,	 88%):	 1H	NMR	 (300	MHz,	 CDCl3)	 δ	
7.34-7.21	(m,	5H),	4.33-4.07	(m,	2H),	3.80	(d,	J	=	18.0	Hz,	1H),	3.63	
(d,	J	=	18.0	Hz,	1H),	3.14	(d,	J	=	17.3	Hz,	1H),	3.10	(d,	J	=	17.3	Hz,	1H),	
1.53	 (s,	 9H),	 1.25	 (t,	 J	 =	 7.1	 Hz,	 3H).	 13C	 NMR	 (75	MHz,	 CDCl3)	 δ	
174.3,	135.2,	130.3,	128.2,	127.0,	76.8,	61.8,	59.7,	43.1,	28.2,	14.2.	
HRMS:	 m/z	 calculated	 for	 [C16H24O4N2Na]
+:	 331.1628;	 found:	
331.1621.	The	enantiomeric	excess	was	determined	by	HPLC	using	a	
Chiralpak	OJ-H	 column	 [hexane:iPrOH	 (98:2)];	 flow	 rate	 1	mL/min;	
30	°C,	τmajor	=	13.6	min,	τminor	=	15.0	min	(58%	ee);	[α]D
27	=	+1.52		(c	
0.6,	CHCl3).	
[(S)-4f]:	Yellow	oil	(150	mg,	77%).	1H	NMR	(400	MHz,	CDCl3)	δ	7.30-
7.21	(m,	3H),	7.15	(d,	J	=	6.8	Hz,	2H,),	4.14	(m,	2H),	3.65	(d,	J	=	18.0	
Hz,	 1H),	 3.56	 (d,	 J	 =	 18.0	 Hz,	 1H),	 3.54	 (s,	 1H),	 2.84-2.80	 (m,	 1H),	
2.54-2.45	(m,	1H),	2.11-2.03	(m,	2H),	1.48	(s,	9H),	1.22	(t,	J	=	6.8	Hz,	
3H).	 13C	NMR	(100	MHz,	CDCl3)	δ	174.9,	141.4,	128.4,	126.0,	76.8,	
76.0,	 61.9,	 60.1,	 38.6,	 29.6,	 28.2,	 14.3.	 HRMS:	m/z	 calculated	 for	
[C17H26N2O4Na]
+:	 345.1785;	 found:	 345.1780.	 The	 enantiomeric	
excess	 was	 determined	 by	 HPLC	 using	 a	 Chiralpak	 AD-H	 column	
[hexane/i-PrOH	(80:20)];	flow	rate	1	mL/min;	τmajor	=	6.1	min,	τminor	
=	5.6	min	(64%	ee);	[α]D
20	=	+21.9	(c	1.0,	CHCl3).	
[(R)-4h]:	White	solid	(141	mg,	80%);	M.P.:	100-102	°C.	1H	NMR	(400	
MHz,	CDCl3)	δ	7.64	(d,	J	=	7.2	Hz,	2H),	7.44-7.26	(m,	3H),	4.31-4.17	
(m,	2H),	4.16	(d,	J	=	17.6	Hz,	1H),	3.98	(s,	1H),	3.81	(d,	J	=	17.6	Hz,	
1H),	1.53	(s,	9H),	1.25	(t,	J	=	7.2	Hz,	3H).	13C	NMR	(100	MHz,	CDCl3)	δ	
173.8,	139.4,	128.3,	128.2,	125.7,	77.2,	76.8,	62.4,	60.6,	28.2,	14.2.	
HRMS:	 m/z	 calculated	 for	 [C15H22N2O4Na]
+:	 317.1472;	 found:	
317.1468.	The	enantiomeric	excess	was	determined	by	HPLC	using	a	
Chiralpak	 AD-H	 column	 [hexane/i-PrOH	 (80:20)];	 flow	 rate	 1	
mL/min;	τmajor	=	6.6	min,	τminor	=	7.6	min	 (89%	ee);	 [α]D
20	=	+8.3	 (c	
1.0,	CHCl3).	
[(R)-4i]:	Yellow	oil	(174	mg,	90%).	1H	NMR	(400	MHz,	CDCl3)	δ	7.78	
(d,	J	=	8.0	Hz,	2H),	7.64	(d,	J	=	8.0	Hz,	2H),	4.29-4.16	(m,	2H),	4.12	(s,	
1H),	4.08	(d,	J	=	18.0	Hz,	1H),	3.75	(d,	J	=	18.0	Hz,	1H),	1.49	(s,	9H),	
1.23	 (t,	 J	=	7.2	Hz,	3H).	 13C	NMR	 (100	MHz,	CDCl3)	δ	172.7,	144.6,	
132.1,	126.8,	118.5,	112.2,	77.1,	76.8,	63.0,	60.5,	28.2,	14.2.	HRMS:	
m/z	calculated	for	[C16H21N3O4Na]
+:	342.1424;	found:	342.1419.	The	
enantiomeric	excess	was	determined	by	HPLC	using	a	Chiralpak	AD-
H	column	[hexane/i-PrOH	(80:20)];	flow	rate	1	mL/min;	τmajor	=	10.6	
min,	τminor	=	11.6	min	(88%	ee);	[α]D
20	=	+13.6	(c	1.3,	CHCl3).	
[(R)-4j]:		White	solid	(181	mg,	83%);	M.P.:	102-104	°C.	1H	NMR	(400	
MHz,	CDCl3)	δ	7.80	(s,	1H),	7.51	(d,	J	=	8.5	Hz,	1H),	7.45	(d,	J	=	8.5	
Hz,	 1H),	 4.39-4.16	 (m,	 2H),	 4.09	 (s,	 1H),	 4.09	 (d,	 J	 =	 17.9	 Hz,	 1H),	
3.77	 (d,	 J	 =	 17.9	Hz,	 1H),	 1.54	 (s,	 9H),	 1.28	 (t,	 J	 =	 7.1	Hz,	 3H).	 13C	
NMR	 (100	MHz,	 CDCl3)	 δ	 173.0,	 139.6,	 132.6,	 132.5,	 130.3,	 128.2,	
125.4,	76.8,	 76.5,	 62.9,	 60.5,	 28.2,	 14.2.	HRMS:	m/z	calculated	 for	
[C15H20Cl2N2O4Na]
+:	 385.0692;	 found:	 385.0689.	 The	 enantiomeric	
excess	 was	 determined	 by	 HPLC	 using	 a	 Chiralpak	 AD-H	 column	
[hexane/i-PrOH	(80:20)];	flow	rate	1	mL/min;	τmajor	=	5.6	min,	τminor	
=	6.3	min	(86%	ee);	[α]D
20	=	+12.3	(c	1.0,	CHCl3).	
[(R)-4k]:	Yellowish	 oil	 (162	mg,	 82%):	 1H	NMR	 (300	MHz,	 CDCl3)	 δ	
7.51	(td,	J	=	8.7,	6.3	Hz,	1H),	688-6.78	(m,	1H),	6.74	(ddd,	J	=	11.3,	
8.7,	2.6	Hz,	1H),	4.25-4.08	(m,	2H),	4.11	(s,	1H),	4.09	(d,	J	=	17.8	Hz,	
1H),	3.96	(d,	J	=	17.8	Hz,	1H),	1.45	(s,	9H),	1.15	(t,	J	=	7.1	Hz,	3H).	13C	
NMR	(75	MHz,	CDCl3)	δ	173.0,	162.9	(dd,	J	=	250.2,	12.3	Hz),	160.4	
(dd,	 J	 =	 252.0,	 11.9	Hz),	 129.1	 (dd,	 J	 =	 9.8,	 5.3	Hz),	 123.4	 (dd,	 J	 =	
12.6,	3.9	Hz),	111.1	 (dd,	 J	=	21.0,	3.5	Hz),	104.6	 (dd,	 J	=	26.6,	25.6	
Hz),	77.2,	74.9	(d,	J	=	2.0	Hz),	62.5,	58.3	(d,	J	=	3.6	Hz),	28.1,	14.0.	19F	
NMR	(283	MHz,	CDCl3)	δ	−107.49	(d,	J	=	8.7	Hz),	−109.87	(d,	J	=	8.7	
Hz).	HRMS:	m/z	calculated	for	[C15H20O4N2F2Na]
+:	353.1283;	found:	
353.1276.	The	enantiomeric	excess	was	determined	by	HPLC	using	a	
Chiralpak	AD-H	column	[hexane:iPrOH	(80:20)];	flow	rate	1	mL/min;	
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30	°C,	τmajor	=	5.7	min,	τminor	=	6.7	min	(90	%	ee);	[α]D
27	=	+2.5	(c	0.7,	
CHCl3).	
[(R)-4l]:	 Yellowish	 oil	 (142	mg,	 79%):	 1H	 NMR	 (300	MHz,	 CDCl3)	 δ	
7.20	(dd,	J	=	5.1,	1.2	Hz,	1H),	7.09	(dd,	J	=	3.6,	1.2	Hz,	1H),	6.92	(dd,	J	
=	5.1,	3.6	Hz,	1H),	4.30-4.09	(m,	2H),	4.18	(s,	1H),	4.02	(d,	J	=	18.0	
Hz,	1H),	3.79	(d,	J	=	18.0	Hz,	1H),	1.46	(s,	9H),	1.20	(t,	J	=	7.1	Hz,	3H).	
13C	NMR	(75	MHz,	CDCl3)	δ	172.9,	143.9,	127.1,	125.5,	124.7,	76.9,	
76.1,	 62.7,	 61.4,	 28.2,	 14.2.	 HRMS:	 m/z	 calculated	 for	
[C13H20O4N2NaS]
+:	 293.1860;	 found:	 293.1851.	 The	 enantiomeric	
excess	 was	 determined	 by	 HPLC	 using	 a	 Chiralpak	 AD-H	 column	
[hexane:iPrOH	(80:20)];	flow	rate	1	mL/min;	30	°C,	τmajor	=	6.4	min,	
τminor	=	7.7	min	(85%	ee);	[α]D
27	=	+3.8		(c	0.4,	CHCl3).	
General	procedure	for	the	synthesis	of	α-hydroxy-β-amino	esters	
5		
Following	 the	 general	 procedure	 for	 the	 catalytic	 enantioselective	
reactions	 of	 hydrazone	 1	 (1.2	 mmol)	 with	 α-keto	 esters	 2	 (0.6	
mmol).	 After	 consumption	 of	 starting	 material,	 the	 solvent	 was	
removed	 in	 vacuo	 and	 the	 residue	was	dissolved	 in	Et2O	 (5.5	mL),	
cooled	 to	 0	 °C,	 and	 HCl	 (6	 M,	 2.5	 mL)	 was	 added.	 The	 reaction	
mixture	was	 allowed	 to	warm	 to	 rt,	 stirred	 for	 2	 h,	 and	 extracted	
with	Et2O	(2	×	5	mL)	and	CH2Cl2	 (2	×	5	mL).	The	combined	organic	
layer	was	dried	over	Na2SO4	and	concentrated	in	vacuo	to	afford	α-
hydroxy	aldehyde	12.	p-Anisidine	(121	mg,	0.9	mmol)	and	NaCNBH3	
(88	mg,	1.4	mmol)	were	added	 to	a	 solution	of	 crude	aldehyde	 in	
CH2Cl2	 (3	 mL)	 at	 room	 temperature.	 The	 reaction	 mixture	 was	
stirred	 for	 2-3	 h,	 H2O	 was	 added	 and	 the	 mixture	 was	 extracted	
with	CH2Cl2	(3	×	5	mL).	The	combined	organic	layer	was	dried	over	
Na2SO4	 and	 concentrated	 in	 vacuo.	 Flash	 chromatography	
(hexane/EtOAc)	 afforded	 the	 corresponding	 β-amino-α-
hydroxyester	5.	
Ethyl	 (S)-2-hydroxy-2-{[(4-methoxyphenyl)amino]methyl}-3-
methylbutanoate	 [(S)-5a]:	Yellowish	oil	 (83	mg,	49%):1H	NMR	(300	
MHz,	 CDCl3)	 δ	 6.73-6.63	 (m,	 2H),	 6.60-6.48	 (m,	 2H),	 4.22-3.98	 (m,	
2H),	3.66	(s,	3H),	3.44	(br	s,	1H),	3.40	(d,	J	=	12.0	Hz,	1H),	3.18	(d,	J	=	
12.0	Hz,	1H),	1.99	(hept,	J	=	6.8	Hz,	1H),	1.16	(t,	J	=	7.1	Hz,	3H),	0.92	
(d,	J	=	6.8	Hz,	3H),	0.82	(d,	J	=	6.8	Hz,	3H).	13C	NMR	(75	MHz,	CDCl3)	
δ	 175.9,	 152.5,	 142.5,	 115.2,	 114.7,	 80.1,	 62.1,	 55.8,	 50.7,	 33.9,	
17.3,	16.4,	14.6.	HRMS:	m/z	 calculated	for	 [C15H24NO4]
+:	282.1700;	
found:	282.1693.	The	enantiomeric	excess	was	determined	by	HPLC	
using	a	Chiralpak	AD-H	column	[hexane:iPrOH	(80:20)];	 flow	rate	1	
mL/min;	 30	 °C,	 τmajor	 =	 7.7	min,	 τminor	 =	 9.9	min	 (61%	ee);	 [α]D
23	 =	
+4.5	(c	0.9,	CHCl3).	
Ethyl	 (S)-2-hydroxy-2-{[(4-methoxyphenyl)amino]methyl}	
pentanoate	 [(S)-5c]:	 Yellow	 oil	 (67	 mg,	 40%).	 1H	 NMR	 (300	 MHz,	
CDCl3)	δ	6.75	(d,	J	=	9.0	Hz,	2H),	6.61	(d,	J	=	9.0	Hz,	2H),	4.26-4.08	
(m,	2H),	3.74	(s,	3H),	3.57	(br	s,	1H),	3.49	(d,	J	=	12.3	Hz,	2H),	3.15	
(d,	J	=	12.3	Hz,	2H),	1.76-1.65	(m,	2H),	1.57-1.41	(m,	1H),	1.24	(t,	J	=	
14.3	Hz,	3H),	1.20-1.07	(m,	1H),	0.92	(t,	J	=	7.3	Hz,	3H).	13C	NMR	(75	
MHz,	 CDCl3)	 δ	 175.7,	 152.6,	 142.1,	 115.3,	 114.8,	 77.6,	 62.1,	 55.8,	
52.7,	39.1,	16.6,	14.2,	14.1.	HRMS:	m/z	calculated	for	[C15H23NO4]
+:	
282.1635;	 found:	 282.1630.	 The	 enantiomeric	 excess	 was	
determined	by	HPLC	using	a	Chiralpak	AD-H	column	[hexane/i-PrOH	
(80:20)];	flow	rate	1	mL/min;	τmajor	=	8.8	min,	τminor	=	11.5	min	(55%	
ee);	[α]D
20	=	–4.9	(c	0.5,	CHCl3).	
Ethyl	(S)-2-hydroxy-2-{[(4-methoxyphenyl)amino]methyl}	octanoate	
[(S)-5d]:	 Yellowish	 oil	 (97	 mg,	 50%):	 1H	 NMR	 (300	 MHz,	 CDCl3)	 δ	
6.73-6.64	(m,	2H),	6.61-6.54	(m,	2H),	4.20-3.99	(m,	2H),	3.67	(s,	3H),	
3.43	(d,	J	=	12.3	Hz,	1H),	3.10	(d,	J	=	12.3	Hz,	1H),	1.74-1.55	(m,	2H),	
1.49-1.33	 (m,	1H),	1.27-1.13	 (m,	9H),	1.12-0.94	 (m,	1H)	0.80	 (t,	 J	=	
6.7	Hz,	3H).	13C	NMR	(75	MHz,	CDCl3)	δ	175.7,	152.8,	141.8,	115.5,	
114.7,	77.6,	62.2,	55.8,	52.9,	37.0,	31.6,	29.3,	23.1,	22.5,	14.2,	14.0.	
HRMS:		m/z	calculated	for	[C18H30NO4]
+:	324.2095;	found:	324.2063.	
The	enantiomeric	excess	was	determined	by	HPLC	using	a	Chiralpak	
AD-H	column	 [hexane:iPrOH	 (80:20)];	 flow	rate	0.7	mL/min;	30	 °C,	
τmajor	 =	 10.9	 min,	 τminor	 =	 12.1	 min	 (61%	 ee);	 [α]D
27	 =	 +7.4	 (c	 1.6,	
CHCl3).	
Ethyl	 (S)-2-benzyl-2-hydroxy-3-[(4-methoxyphenyl)amino]	
propanoate	[(S)-5e]:	Yellowish	oil	(89	mg,	45%):	1H	NMR	(300	MHz,	
CDCl3)	 δ	 7.36-7.22	 (m,	 5H),	 6.84-6.77	 (m,	 2H),	 6.70-6.64	 (m,	 2H),	
4.20-4.09	(m,	2H),	3.78	(s,	3H),	3.67	(d,	J	=	12.2	Hz,	1H),	3.48	(br	s,	
1H),	3.30	(d,	J	=	12.2	Hz,	1H),	3.13	(d,	J	=	13.6	Hz,	1H),	3.06	(d,	J	=	
13.6	 Hz,	 1H),	 1.25	 (t,	 J	 =	 7.1	 Hz,	 3H).13C	 NMR	 (75	MHz,	 CDCl3)	 δ	
174.6,	152.6,	142.2,	135.2,	130.1,	128.2,	127.1,	115.2,	114.8,	78.2,	
62.2,	55.8,	52.5,	43.1,	14.1.	HRMS:	m/z	calculated	for	[C19H24O4N]
+:	
330.1700;	 found:	 330.1691.	 The	 enantiomeric	 excess	 was	
determined	by	HPLC	using	a	Chiralpak	OJ-H	column	 [hexane:iPrOH	
(90:10)];	 flow	 rate	1	mL/min;	30	 °C,	 τmajor	 =	27.7	min,	 τminor	 =	29.9	
min	(51%	ee);	[α]D
27	=	+10.7		(c	1.5,	CHCl3).	
Ethyl	 (S)-2-hydroxy-2-{[(4-methoxyphenyl)amino]methyl}-4-
phenylbutanoate	 [(S)-5f]:	Yellowish	oil	 (84	mg,	41%):	1H	NMR	(400	
MHz,	 CDCl3)	 δ	 7.36-7.27	 (m,	 2H),	 7.27-7.16	 (m,	 3H),	 6.86-6.73	 (m,	
2H),	6.68-6.59	(m,	2H),	4.16	(qq,	J	=	10.7,	7.1	Hz,	2H),	3.77	(s,	3H),	
3.71	 (br	 s,	1H),	3.55	 (d,	 J	 =	12.4	Hz,	1H),	3.24	 (d,	 J	 =	12.3	Hz,	1H),	
2.86	(ddd,	J	=	13.6,	10.9,	5.6	Hz,	1H),	2.50	(ddd,	J	=	13.6,	11.2,	5.8	
Hz,	 1H),	 2.18-2.03	 (m,	 1H),	 1.27	 (t,	 J	 =	 7.1	 Hz,	 1H).	 13C	NMR	 (100	
MHz,	CDCl3)	δ	175.5,	152.6,	142.2,	141.3,	128.5,	128.4,	126.1,	115.2,	
114.8,	77.4,	62.4,	55.8,	52.8,	38.6,	29.7,	14.2.	HRMS:	m/z	calculated	
for	 [C20H25NO4]
+:	 343.1856;	 found:	 343.1847.	 The	 enantiomeric	
excess	 was	 determined	 by	 HPLC	 using	 a	 Chiralpak	 AD-H	 column	
[hexane:iPrOH	(80:20)];	flow	rate	1	mL/min;	30	°C,	τmajor	=	9.8	min,	
τminor	=	12.4	min	(62%	ee);	[α]D
23	=	−6.3		(c	1.0,	CHCl3).	
Ethyl	 (R)-2-hydroxy-3-[(4-methoxyphenyl)amino]-2-phenyl	
propanoate	 [(R)-5h]:	 Yellowish	 oil	 (101	 mg,	 51%):	 1H	 NMR	 (300	
MHz,	CDCl3)	δ	7.67	(d,	J	=	7.6	Hz,	2H),	7.45-7.32	(m,	3H),	6.78	(d,	J	=	
8.8	Hz,	2H),	6.68	(d,	J	=	8.8	Hz,	2H),	4.22	(q,	J	=	7.2	Hz,	2H),	4.19	(br	
s,	1H)4.01	(d,	J	=	12.4	Hz,	1H),	3.75	(s,	3H),	3.39	(d,	J	=	12.4	Hz,	1H),	
1.23	 (t,	 J	=	7.2	Hz,	3H).	 	 13C	NMR	 (75	MHz,	CDCl3):	δ	174.2,	152.7,	
142.2,	 139.7,	 128.5,	 128.2,	 125.5,	 115.5,	 114.8,	 78.7,	 62.8,	 55.8,	
53.4,	14.0.	HRMS:	m/z	calculated	for	[C18H23NO4]
+:	316.1543;	found:	
316.1540.	The	enantiomeric	excess	was	determined	by	HPLC	using	a	
Chiralpak	AD-H	column	[hexane:iPrOH	(80:20)];	flow	rate	1	mL/min;	
30	°C,	τmajor	=	16.2	min,	τminor	=	12.6	min	(90%	ee);	[α]D
20	=	+11.7		(c	
1.01,	CHCl3).	
Ethyl	 (R)-2-(4-cyanophenyl)-2-hydroxy-3-[(4-methoxyphenyl)	
amino]propanoate	[(R)-5i]:	Yellowish	oil	(94	mg,	46%):	1H	NMR	(300	
MHz,	CDCl3)	δ	7.73	(d,	J	=	8.6	Hz,	2H),	7.59	(d,	J	=	8.6	Hz,	2H),	6.72-
6.66	(m,	2H),	6.64-6.55	(m,	2H),	4.13	(q,	J	=	7.1	Hz,	2H),	3.87	(d,	J	=	
12.6	Hz,	1H),	3.66	(s,	3H),	3.28	(d,	J	=	12.6	Hz,	1H),	1.16	(t,	J	=	7.1	Hz,	
3H).	 13C	NMR	 (75	MHz,	CDCl3)	δ	172.1,	151.9,	143.7,	140.6,	131.2,	
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125.5,	 117.5,	 114.6,	 113.8,	 111.2,	 77.5,	 62.3,	 54.7,	 52.6,	 13.0.	
HRMS:	 m/z	 calculated	 for	 [C19H22N2O4]
+:	 341.1496;	 found:	
341.1496.	The	enantiomeric	excess	was	determined	by	HPLC	using	a	
Chiralpak	IB	column	[hexane:iPrOH	(90:10)];	flow	rate	1	mL/min;	30	
°C,	τmajor	=	15.9	min,	τminor	=	14.2	min	(90%	ee);	[α]D
23	=	+11.3		(c	1.2,	
CHCl3).	
Ethyl	 (R)-2-(3,4-dichlorophenyl)-2-hydroxy-3-[(4-methoxyphenyl)	
amino]propanoate	 [(R)-5j]:	Yellow	oil	 (106	mg,	46%).	 1H	NMR	(400	
MHz,	CDCl3)	δ	7.82	(d,	J	=	2.1	Hz,	1H),	7.54	(dd,	J	=	8.5,	2.1	Hz,	1H),	
7.47	(d,	J	=	8.5	Hz,	1H),	6.83-6.77	(m,	2H),	6.73-6.66	(m,	2H),	4.27-
4.24	(m,	2H),	3.94	(d,	J	=	12.5	Hz,	1H),	3.77	(s,	3H),	3.36	(d,	J	=	12.5	
Hz,	1H),	1.27	(t,	J	=	7.1	Hz,	3H).	13C	NMR	(100	MHz,	CDCl3)	δ	173.3,	
152.9,	141.7,	139.8,	132.7,	132.5,	130.4,	127.9,	125.1,	115.6,	114.8,	
78.0,	 63.3,	 55.8,	 53.6,	 14.0.	 HRMS:	 m/z	 calculated	 for	
[C18H20NO4Cl2]
+:	 384.0764;	 found:	 384.0757.	 The	 enantiomeric	
excess	 was	 determined	 by	 HPLC	 using	 a	 Chiralpak	 AD-H	 column	
[hexane/i-PrOH	(80:20)];	flow	rate	1	mL/min;	τmajor	=	11.6	min,	τminor	
=	10.3	min	(84%	ee);	[α]D
20	=	+10.4	(c	0.5,	CHCl3).	
Ethyl	 (R)-2-(2,4-difluorophenyl)-2-hydroxy-3-[(4-methoxyphenyl)	
amino]propanoate	 [(R)-5k]:	 Yellowish	 oil	 (93	 mg,	 44%):	 1H	 NMR	
(300	MHz,	CDCl3)	 δ	 7.55	 (m,	 1H),	 6.87-6.79	 (m,	 1H),	 6.79-6.73	 (m,	
1H),	6.73-6.67	 (m,	2H),	6.65-6.58	 (m,	2H),	4.12	 (q,	 J	 =	7.1	Hz,	2H),	
3.97	(d,	J	=	12.5	Hz,	1H),	3.47	(d,	J	=	12.5	Hz,	1H),	1.12	(t,	J	=	7.1	Hz,	
3H).	13C	NMR	(75	MHz,	CDCl3)	δ	173.3,	162.9	(dd,	J	=	250.2,	12.2	Hz),	
160.4	 (dd,	 J	=	250.9,	11.8	Hz),	153.0,	141.7,	128.9	 (dd,	 J	=	9.7,	5.5	
Hz),	123.4	(dd,	J	=	12.7,	3.9	Hz),	115.6,	114.8,	111.3	(dd,	J	=	21.0,	3.5	
Hz),	104.6	(dd,	J	=	26.6,	25.6	Hz),	75.8	(d,	J	=	2.5	Hz),	62.8,	55.8,	51.4	
(d,	J	=	4.0	Hz),	13.9.	19F	NMR	(283	MHz,	CDCl3)	δ	−108.39	(d,	J	=	8.5	
Hz),	 −109.89	 (d,	 J	 =	 8.5	 Hz).	 HRMS:	 m/z	 calculated	 for	
[C18H21F2NO4]
+:	 352.1355;	 found:	 352.1350.	 The	 enantiomeric	
excess	 was	 determined	 by	 HPLC	 using	 a	 Chiralpak	 IA	 column	
[hexane:iPrOH	 (80:20)];	 flow	 rate	1	mL/min;	30	 °C,	 τmajor	 =9.6	min,	
τminor	=	12.6	min	(93%	ee);	[α]D
23	=	+8.0		(c	1.0,	CHCl3).	
Ethyl	 (R)-2-hydroxy-3-[(4-methoxyphenyl)amino]-2-(thiophen-2-yl)	
propanoate	[(R)-5l]:	Yellowish	oil	(79	mg,	41%):	1H	NMR	(300	MHz,	
CDCl3)	δ	7.20	(dd,	J	=	5.1,	1.2	Hz,	1H),	7.10	(dd,	J	=	3.6,	1.2	Hz,	1H),	
6.93	(dd,	J	=	5.1,	3.6	Hz,	1H),	6.70	(d,	J	=	8.3	Hz,	2H),	6.59	(d,	J	=	8.3	
Hz,	2H),	4.19-4.10	(m,	2H),	4.07	(d,	J	=	6.5	Hz,	1H),	3.66	(s,	3H),	3.38	
(d,	J	=	6.5	Hz,	1H),	1.18	(t,	J	=	7.0	Hz,	3H).	13C	NMR	(75	MHz,	CDCl3)	δ	
173.2,	152.8,	144.1,	141.8,	127.2,	125.4,	124.4,	115.5,	114.6,	77.7,	
63.1,	 55.8,	 54.5,	 14.0.	 HRMS:	 m/z	 calculated	 for	 [C16H21NO4S]
+:	
322.1108;	 found:	 322.1103.	 The	 enantiomeric	 excess	 was	
determined	by	HPLC	using	a	Chiralpak	AD-H	column	[hexane:iPrOH	
(80:20)];	 flow	 rate	1	mL/min;	30	 °C,	 τmajor	 =	19.2	min,	 τminor	 =	15.3	
min	(84%	ee);	[α]D
23	=	+11.8		(c	0.9,	CHCl3).	
General	procedure	for	the	synthesis	of	diols	13		
Following	 the	 general	 procedure	 for	 the	 catalytic	 enantioselective	
reactions	 of	 hydrazone	 1	 (1.2	 mmol)	 with	 α-keto	 esters	 2	 (0.6	
mmol).	 After	 consumption	 of	 starting	 material,	 solvent	 was	
removed	 in	 vacuo	 and	 the	 residue	was	dissolved	 in	Et2O	 (5.5	mL),	
cooled	 to	 0	 ˚C,	 and	 HCl	 (6	 M,	 2.5	 mL)	 was	 added.	 The	 reaction	
mixture	was	allowed	to	warm	to	room	temperature	and	stirred	for	
2	 h.,	 then	 extracted	 with	 Et2O	 (2	 x	 5	 mL)	 and	 CH2Cl2	 (2	 x	 5	 mL).	
Organic	phases	were	dried	over	Na2SO4	and	concentrated	 in	vacuo	
to	afford	α-hydroxy	aldehyde	12.	Bu4NBH4	(112	mg,	0.4	mmol)	was	
added	 to	 a	 solution	 of	 crude	 aldehyde	 in	 CH2Cl2	 (3	 mL)	 at	 room	
temperature.	 The	 reaction	 mixture	 was	 stirred	 for	 2-3	 h.	 Flash	
chromatography	(CH2Cl2/MeOH	97:3)	afforded	the	pure	diols	13.	
Ethyl	 (S)-2-hydroxy-2-(hydroxymethyl)pentanoate	 [(S)-13c]:	 yellow	
oil	 (45	mg,	 43%).	 [α]D
25	 =	 −5.6	 	 (c	 1.7,	 CHCl3,	 50%	ee).	 Lit.	 [α]D
25	 =	
11.1		[c	4.0,	CHCl3,	44%	ee,	(R)].
16a	
Ethyl	(S)-2-benzyl-2,3-dihydroxypropanoate	[(S)-13e]:	yellow	oil	(85	
mg,	63%).	[α]D
25	=	+9.8		(c	0.8,	CHCl3,	60%	ee).	Lit.	[α]D
25	=	+10.4	(c	
0.9,	CHCl3,	76%	ee).
16b		
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